Daming Gao

Chinese Academy of Sciences — China

Medicine · Health Sciences

47h-index8.9kcitations192works6.22yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cholangiocarcinoma and Gallbladder Cancer Studies(49), Ubiquitin and proteasome pathways(40), RNA modifications and cancer(37), Peptidase Inhibition and Analysis(22), Cancer-related Molecular Pathways(18)

Publications192 total

Supplementary Table S4 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S6 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S2 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S5 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S1 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S3 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Table S7 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
Supplementary Figures S1-9 from An Inflammatory Checkpoint Generated by <i>IL1RN</i> Splicing Offers Therapeutic Opportunity for <i>KRAS</i>-Mutant Intrahepatic Cholangiocarcinoma
2025Open Access
RNF168 dephosphorylation ameliorates cognitive decline in Aβ-based mouse models of Alzheimer’s disease
Acta Neuropathologica Communications·2025Open Access
A rapid imaging-based screen for induced-proximity degraders identifies a potent degrader of oncoprotein SKP2
Nature Biotechnology·2025· 8 cited
Correction: SCFβ-TRCP suppresses angiogenesis and thyroid cancer cell migration by promoting ubiquitination and destruction of VEGF receptor 2
The Journal of Experimental Medicine·2025Open Access
Correction: SCFFBXW7/GSK3β-Mediated GFI1 Degradation Suppresses Proliferation of Gastric Cancer Cells
Cancer Research·2025Open Access
SCFFbw7 Modulates the NFκB Signaling Pathway by Targeting NFκB2 for Ubiquitination and Destruction
Cell Reports·2025Open Access
Figure S6 from Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
2025Open Access
Supplementary Table S1 from Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
2025Open Access
Supplementary Table S2 from Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
2025Open Access
Figure S5 from Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
2025Open Access
Figures S1 from Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
2025Open Access
Figures S3 from Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
2025Open Access
Data from Mutant KRAS and CK2 Cooperatively Stimulate SLC16A3 Activity to Drive Intrahepatic Cholangiocarcinoma Progression
2025Open Access
page 1 of 10Next →

Frequent Co-authors

Wenyi Wei(25), Hiroyuki Inuzuka(22), Lixin Wan(18), Hu Zhou(12), Shavali Shaik(11), Pengda Liu(10), Hidefumi Fukushima(10), Qiang Gao(9), Jia Fan(9), Liangqing Dong(8), Bing Zhang(8), Steven P. Gygi(8), Zhiwei Wang(8), Hongwen Zhu(7), Alan W. Lau(7), Xiaoying Wang(6), Jian Zhou(6), Li Ding(6), Bo Zhai(6), John M. Asara(6)